Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-1 vs CERIANNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
Hypothyroidism, primary, secondary, or tertiary,Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
2.5 mg orally once daily
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Levothyroxine is deiodinated to liothyronine in peripheral tissues via iodothyronine deiodinases (DIO1, DIO2). Liothyronine undergoes deiodination and conjugation (glucuronidation, sulfation) in liver.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
>99% bound; T4 bound to thyroxine-binding globulin (TBG: ~70%), transthyretin (10-15%), and albumin (15-20%); T3 binds less avidly to TBG and albumin.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd: approximately 0.1-0.2 L/kg for T4; 0.3-0.5 L/kg for T3; reflects distribution primarily into extracellular fluid and limited tissue penetration for T4, wider distribution for T3.
0.5-0.7 L/kg, indicating moderate tissue distribution.
Oral: 50-80% for T4 (absorption depends on formulation and food); T3 nearly completely absorbed (>90%).
Oral bioavailability: 60-80%.
No specific GFR-based dose adjustment required; however, in severe renal failure, monitor thyroid function closely as drug clearance may be altered.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No specific Child-Pugh based dose adjustment; caution in severe hepatic impairment due to altered metabolism of thyroid hormones.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
Weight-based dosing for hypothyroidism: initial 12.5-25 mcg levothyroxine equivalent per day, adjusted based on TSH and free T4 levels. Not recommended for children due to fixed combination ratio.
Not approved for pediatric use
Start with lower dose (e.g., half tablet) and titrate slowly; monitor for cardiac side effects due to increased sensitivity to thyroid hormones.
No specific dose adjustment; monitor renal function due to age-related decline
No black box warning.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
Cardiovascular toxicity with overdosage; may exacerbate angina, arrhythmias, hypertension. Caution in patients with diabetes mellitus (may increase blood glucose) and adrenal insufficiency. Monitor thyroid function tests and adjust dose.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Avoid high-fiber foods, grapefruit juice, and soy products within 4 hours of taking Euthyroid-1 as they may interfere with absorption. Maintain consistent iodine intake; avoid drastic increases in cruciferous vegetables (e.g., broccoli, kale) without medical advice. Calcium-fortified foods and iron-rich foods should be separated by at least 4 hours.
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits, preterm delivery, and low birth weight. Levothyroxine itself is not teratogenic; the FDA pregnancy category is A. No increased risk of congenital malformations has been reported with therapeutic doses. In the first trimester, adequate maternal T4 is critical for fetal brain development. In the second and third trimesters, placental transfer of levothyroxine is minimal as fetal thyroid function matures. Untreated hyperthyroidism from over-replacement may increase risk of fetal tachycardia, growth restriction, and preterm birth.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Levothyroxine is excreted into breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. The estimated daily infant dose through breast milk is less than 1% of the maternal dose, which is negligible. No adverse effects in infants have been reported. The American Academy of Pediatrics considers levothyroxine compatible with breastfeeding. Monitoring of infant thyroid function is not routinely required but may be considered if maternal dose is high.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Pregnancy increases total body water, plasma volume, and renal clearance, and alters thyroid-binding globulin synthesis, leading to increased levothyroxine requirements. Dose adjustments are often needed as early as 4-6 weeks gestation. Typically, the dose is increased by 30-50% from preconception baseline. For patients already on levothyroxine, increase dose by 2 additional tablets per week (e.g., 2 extra doses) or approximately 30% upon confirmation of pregnancy. Monitor TSH every 4-6 weeks and adjust to maintain TSH <2.5 m IU/L in the first trimester and <3.0 m IU/L in later trimesters. After delivery, reduce dose to prepregnancy level and check TSH 6 weeks postpartum.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
Euthyroid-1 contains levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Monitor TSH, free T4, and free T3 levels to avoid overtreatment, especially due to T3 component. Use with caution in elderly and patients with cardiovascular disease; start with lower doses. T3 has a shorter half-life (about 1 day) vs T4 (7 days); consider this when interpreting labs. Drug interactions: iron, calcium, antacids, and bile acid sequestrants may reduce absorption; separate by at least 4 hours.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Take exactly as prescribed at the same time each day, usually in the morning on an empty stomach with water.,Do not stop or change dose without consulting your doctor; symptoms may take weeks to improve.,Inform your doctor of all other medications and supplements you take, especially iron, calcium, and antacids.,Report symptoms of hyperthyroidism (rapid heart rate, chest pain, sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Store at room temperature away from moisture and heat; keep out of reach of children.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-1 vs CERIANNA, answered by our medical review team.
EUTHROID-1 is a Thyroid Hormone Replacement that works by Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.. CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-1 and CERIANNA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-1 is: One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.. The standard adult dose of CERIANNA is: 2.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-1 and CERIANNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-1 is classified as Category C. EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits,. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.